Macrogenics (MGNX) Provides Vobramitamab Duocarmazine Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
BTIG Downgrades MacroGenics (MGNX) to Neutral
July 31, 2024 4:18 PM EDTBTIG analyst Kaveri Pohlman downgraded MacroGenics (NASDAQ: MGNX) from Buy to Neutral.
The analyst comments "MacroGenics has discontinued the Tamarack study, evaluating vobra duo for mCRPC, after a review of its risk/benefit profile. This decision follows the study's IDMC recommendation to discontinue treatment for the remaining study participants who were eligible to receive additional doses. For reference, the majority... More
